OrthoPediatrics (NASDAQ:KIDS) Sets New 12-Month High – Still a Buy?

OrthoPediatrics Corp. (NASDAQ:KIDS) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $24.56 and last traded at $24.24, with a volume of 231374 shares changing hands. The stock had previously closed at $23.28.

Analysts Set New Price Targets

KIDS has been the subject of several research analyst reports. Needham & Company LLC upped their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. BTIG Research restated a “buy” rating and issued a $24.00 target price on shares of OrthoPediatrics in a research note on Friday, May 1st. Finally, Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a research report on Friday, April 24th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus target price of $25.89.

OrthoPediatrics Trading Up 4.1%

The company’s 50 day moving average price is $19.67 and its 200 day moving average price is $17.98. The company has a market cap of $632.91 million, a price-to-earnings ratio of -14.43 and a beta of 0.98. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. Research analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Institutional Trading of OrthoPediatrics

A number of institutional investors and hedge funds have recently made changes to their positions in KIDS. Russell Investments Group Ltd. boosted its stake in shares of OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after acquiring an additional 1,139 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after acquiring an additional 2,561 shares in the last quarter. Caption Management LLC acquired a new stake in OrthoPediatrics in the 3rd quarter worth approximately $54,000. BNP Paribas Financial Markets lifted its holdings in OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the last quarter. Finally, State of Wyoming boosted its position in OrthoPediatrics by 189.7% during the fourth quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after purchasing an additional 4,467 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.